Conference ReCAP

Key Studies on Diabetes Comorbidities From ADA 2022


 

Dr Anastassios Pittas, Chief of Endocrinology at Tufts Medical Center in Boston, discusses key data from the American Diabetes Association Scientific Sessions 2022 on the management of common comorbidities in diabetes.

Dr Pittas looks first at a prespecified analysis of the SURPASS-4 trial, which highlighted the role of tirzepatide on kidney outcomes in patients with type 2 diabetes.

He then discusses results of the SPLENDID trial in which patients with diabetes who received bariatric surgery for weight loss showed reduced rates of cancer.

Finally, Dr Pittas reports on a study examining the effect of food insecurity and diet quality on maintaining good cholesterol levels in diabetes.

--

Anastassios G. Pittas, MD, Chief, Division of Endocrinology, Diabetes, and Metabolism; Co-director, Diabetes and Lipid Center; Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts

Anastassios G. Pittas, MD, has disclosed no relevant financial relationships.

Recommended Reading

Diabetes tied to risk of long COVID, too
MDedge Endocrinology
Heart failure: Medicare cost sharing may put quadruple therapy out of reach
MDedge Endocrinology
Experts elevate new drugs for diabetic kidney disease
MDedge Endocrinology
Ultra-processed: Doctors debate whether putting this label on foods is useful
MDedge Endocrinology
What’s the best time of day to exercise? It depends on your goals
MDedge Endocrinology
Could a type 2 diabetes drug tackle kidney stones?
MDedge Endocrinology
iLet system simplifies insulin delivery for type 1 diabetes
MDedge Endocrinology
Type 2 Diabetes and COVID-19
MDedge Endocrinology
New data, film highlight islet cell transplantation progress
MDedge Endocrinology
Type 1 diabetes control worse in racially segregated teens
MDedge Endocrinology